Clinical Trials for Colorectal Cancer
522 colorectal cancer trials indexed, 270 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Colorectal Cancer
Colorectal cancer is a type of cancer that starts in the colon or rectum, parts of the large intestine. It develops when cells in the lining of these organs grow uncontrollably, forming tumors. The disease often begins as small, noncancerous clumps of cells called polyps, which can turn into cancer over time. Doctors diagnose colorectal cancer through a combination of tests, including colonoscopy, biopsy, imaging scans, and blood tests. A colonoscopy allows doctors to see inside the colon and rectum to find polyps or tumors and take tissue samples for examination.
Common symptoms of colorectal cancer include changes in bowel habits, such as diarrhea or constipation, blood in the stool, abdominal pain, and unexplained weight loss. The typical age of onset is usually after 50 years, but younger adults can also develop the disease. People with a family history of colorectal cancer, certain genetic conditions, or inflammatory bowel diseases like Crohn’s disease face higher risks. Lifestyle factors such as a diet high in red or processed meats, smoking, heavy alcohol use, and lack of physical activity also contribute to the risk.
Colorectal cancer is a major medical and social concern worldwide. It ranks as the third most common cancer and the second leading cause of cancer-related deaths in the United States. Each year, over 150,000 new cases are diagnosed, and about 53,000 people die from the disease. The economic burden is significant, with billions spent annually on treatment and care. Early detection is critical because the five-year survival rate is around 90% when caught at an early stage, but it drops sharply with advanced disease.
The Colorectal Cancer Treatment Landscape
For patients diagnosed with colorectal cancer, treatment usually begins with surgery to remove the tumor. Surgery is often the first-line standard of care, especially for early-stage disease. Depending on the stage and location of the cancer, surgery may be followed by chemotherapy or radiation therapy to reduce the risk of recurrence. In some cases, chemotherapy is given before surgery to shrink tumors and make removal easier. Treatment plans are tailored to each patient based on tumor characteristics, overall health, and whether the cancer has spread.
When the cancer is more advanced or returns after initial treatment, second- and third-line options become important. Chemotherapy drugs such as fluorouracil (5-FU), oxaliplatin, and irinotecan are commonly used. Targeted therapies that block specific molecules involved in cancer growth, like bevacizumab and cetuximab, may also be prescribed. These drugs belong to classes such as angiogenesis inhibitors and epidermal growth factor receptor (EGFR) inhibitors. Immunotherapy has shown promise for certain subtypes of colorectal cancer, especially those with high microsatellite instability.
Despite these options, gaps remain in treatment effectiveness. Some patients do not respond well to chemotherapy or targeted therapies, and resistance to drugs often develops over time. Side effects like fatigue, nausea, neuropathy, and immune-related reactions can limit treatment tolerance. Research is focused on finding new drugs and combinations, improving biomarkers to predict who will benefit from specific therapies, and reducing side effects. Clinical trials are essential for testing these new approaches and expanding options for patients.
Why Clinical Trials Matter for Colorectal Cancer
Clinical trials offer patients access to new treatments that are not yet widely available. Participating in a trial can provide closer medical monitoring and support during treatment. It also allows patients to contribute to scientific knowledge that may help others in the future. Currently, ClinicalTrials.gov lists 522 colorectal cancer clinical trials, with 270 actively recruiting participants. These trials cover a wide range of approaches, including new drugs, combination therapies, and diagnostic tools.
Joining a clinical trial involves some risks. New treatments may not work better than existing ones and could cause unexpected side effects. Some trials include placebo arms, meaning some participants do not receive the experimental treatment. Additional clinic visits and tests might be required, which can be time-consuming. Patients should carefully weigh potential benefits and risks and discuss them with their healthcare team before enrolling.
Clinical trials for colorectal cancer are sponsored by various organizations, including academic institutions, pharmaceutical companies, and cooperative groups. These sponsors design and fund studies to answer important questions about treatment safety and effectiveness. ClinicalTrials.gov serves as a public registry where patients and doctors can find detailed information about ongoing trials. This transparency helps ensure that research is conducted ethically and that patients have access to trial opportunities.
What to Look for in a Colorectal Cancer Clinical Trial
Clinical trials are divided into phases 1 through 4. Phase 1 trials test safety and dosage in a small group of participants. Phase 2 trials focus on effectiveness and side effects. Phase 3 trials compare new treatments against the current standard. Phase 4 trials happen after approval to monitor long-term effects. For colorectal cancer, most trials are in Phase 1, with 142 studies, followed by 132 in Phase 2. There are 29 trials in Phase 3, and 122 trials without a specified phase. This means many studies are early-stage, exploring safety and initial effectiveness.
Inclusion criteria for colorectal cancer trials often include specific age ranges, commonly adults 18 years or older. Prior treatments may be considered, such as previous chemotherapy or surgery. Some trials require certain biomarkers, like genetic mutations or protein expressions, to be present. Staging is important: many trials focus on advanced or metastatic colorectal cancer, while others include earlier stages. Disease duration and overall health status are also factors for eligibility.
Exclusion criteria help protect participants and maintain clear study results. Patients with serious comorbidities like heart or liver disease may be excluded to reduce risk. Drug interactions are another concern; participants cannot take medications that interfere with the trial drug. Safety thresholds such as low blood counts or poor kidney function can also disqualify participants. These rules ensure the trial is safe and that results are reliable.
Practical considerations are important for patients thinking about joining a trial. Trial duration can vary from a few months to several years. Visit schedules may include frequent hospital trips for tests and treatments. Travel to the trial site might be required, which could be a challenge for some. It is helpful to ask the research team four key questions: What are the potential risks and benefits? How often will I need to visit the clinic? Will there be costs or reimbursements for travel? What happens if I decide to leave the trial early?
Primary Sources and Further Reading
For patients and caregivers seeking more information on colorectal cancer and clinical trials, trusted sources provide detailed and up-to-date content. These websites offer guidance on treatment options, trial participation, and general cancer care. Exploring these resources can help you make informed decisions and prepare for discussions with your healthcare team.
- National Cancer Institute: Colorectal Cancer
- MedlinePlus: Colorectal Cancer
- ClinicalTrials.gov: Colorectal Cancer Trials
- Centers for Disease Control and Prevention: Colorectal Cancer
Latest Research and Emerging Treatments for Colorectal Cancer (2026)
Current colorectal cancer research includes several Phase 3 trials testing new drugs and combinations to improve treatment outcomes. One study is exploring the combination of sotorasib, panitumumab, and FOLFIRI chemotherapy in patients with metastatic colorectal cancer who have a KRAS p.G12C mutation (NCT06252649). Sotorasib targets the KRAS mutation, which is involved in cancer cell growth. Panitumumab blocks a protein called EGFR that helps tumors grow. Together with chemotherapy, this approach aims to control cancer progression more effectively than standard treatments. For patients, this could mean longer periods without cancer growth and potentially better quality of life.
Another important trial is testing the addition of atezolizumab, an immunotherapy drug, to standard chemotherapy in stage III colon cancer patients with deficient DNA mismatch repair (NCT02912559). Atezolizumab helps the immune system recognize and attack cancer cells. This research is looking at whether combining immunotherapy with chemotherapy improves survival compared to chemotherapy alone. If successful, it may offer a new treatment option for patients with this specific genetic profile.
There is also ongoing research on low dose aspirin as an adjuvant treatment for colorectal cancer (NCT02647099). Aspirin is being studied for its potential to improve survival by reducing inflammation and possibly slowing cancer growth. This simple pill treatment could provide a low-cost option to support standard colorectal cancer treatment. Additionally, a trial is evaluating calderasib combined with cetuximab and chemotherapy for advanced colorectal cancer with KRAS G12C mutation (NCT06997497). Calderasib is a targeted drug like sotorasib, designed to inhibit the KRAS mutation. These new drugs for colorectal cancer represent efforts to tailor treatment based on genetic factors, which may help patients receive therapies better suited to their cancer’s biology.
Frequently asked questions about Colorectal Cancer trials
How do I find Colorectal Cancer clinical trials?
The authoritative source for Colorectal Cancer clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 522 colorectal cancer studies are currently indexed. You can search by entering "colorectal cancer" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new colorectal cancer trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Colorectal Cancer trials in?
Across the 522 colorectal cancer trials TrialsAlert indexes, the most common phase is Phase 1. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Colorectal Cancer clinical trials are currently recruiting?
As of the latest scan, 270 colorectal cancer trials have a "Recruiting" status on ClinicalTrials.gov, out of 522 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting colorectal cancer trial matches their tracked condition.
Stay informed about colorectal cancer research
Get a weekly briefing with the trials that matter most.